BioSpace News Archive

Dr. Joseph Stauffer, an anesthesiologist with deep clinical and regulatory experience, fills a key position as Antibe prepares for late-stage development and partnering

Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has extended the action date by three months for the biologics license application (BLA) for lisocabtagene maraleucel (liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy for the treatment of adults with relapsed or refractory (R/R) large B-cell lymphoma after at least two prior therapies. The new Presc

Founded by Versant Ventures to develop medicines that target the innate immune system

IVERIC bio, Inc. announced financial and operating results for the fiscal quarter ended March 31, 2020 and provided a general business update.

Collaboration focuses on advancing innovation with antibody-drug conjugate (ADC)-based conditioning for lentiviral gene therapies

FARXIGA is the first SGLT2 inhibitor proven to significantly reduce the risk of cardiovascular death and hospitalization for heart failure

BrainsWay Ltd. announced that Hadar Levy has been promoted to Senior Vice President and General Manager of North America, and Judith Huber has been appointed the Company’s Senior Vice President and Chief Financial Officer, effective May 11, 2020.

Reports record quarterly revenue of $76.1 million Overall revenue grew 25% year-over-year, with organic growth of 16% Strong order load through first four months

~ Phase 3 LOGICS Study of RECORLEV ® (levoketoconazole) Reaches 41 of 42 Targeted Study Participants Completing the Randomized Withdrawal Phase; One Additional Patient Currently in the Randomized Withdrawal Phase and One Other Patient Scheduled to be Randomized Imminently ~ ~ LOGICS Enrollment to Close on or Before May 14, 2020; Company Expects to Report Top-Line LOGICS Results During the Third Quarter of 2020 ~ ~ Reports KEVEYIS ® (dichlorphenamide) First Quarter 2020 Revenue of $6

Oral Presentation of Initial Results from the Phase 1 ALLO-501 ALPHA Trial in Relapsed/Refractory Non-Hodgkin Lymphoma at the Virtual American Society of Clinical Oncology (ASCO) Annual Meeting